Sugi Predict

Sugi Predict / Compounds / SCHEMBL5344597

SCHEMBL5344597

SCHEMBL5344597

CC(=O)O[C@H]1OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 4/20 0.44
▸ POLB P06746 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ CA1 P00915 3/20 0.42
▸ CA2 P00918 3/20 0.42
▸ CA9 Q16790 3/20 0.42
▸ OGA O60502 1/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ LMNA P02545 1/20 0.36
▸ BCHE P06276 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ CHRM2 P08172 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7156149 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL8590554 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL5350100 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL5390328 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL7026542 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL3546297 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL3570498 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL7154349 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL6949988 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2
SCHEMBL6956183 1.00 PTPN1 (0.44) PTPN1POLBGAACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003002585-A1 [4-(4-CYANOBENZOYL)PHENYL]GLYCOPYRANOSIDE DERIVATIVES, USE OF SAME AS A MEDICAMENT, PRODUCTION METHOD THEREOF AND COMPOSITIONS LABORATOIRES FOURNIER SA (FR) 2003-01-09 — — WO claimed
US-7291726-B2 Process for the preparation of 2′-halo-β-L-arabinofuranosyl nucleosides BUKWANG PHARMACEUTICALS IND CO., LTD. (KR) 2007-11-06 — — US disclosed
US-7258902-B2 Chiral 3,4-dihydro-2H-pyran compounds BASF AKTIENGESELLSCHAFT (DE) 2007-08-21 — — US disclosed
US-7258902-B2 Chiral 3,4-dihydro-2H-pyran compounds BASF AKTIENGESELLSCHAFT (DE) 2007-08-21 — — US disclosed
US-20050230660-A1 Chiral 3,4-dihydro-2h-pyran compounds BASF AKTIENGESELLSCHAFT 2005-10-20 — — US disclosed
US-20050187384-A1 Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides TRIANGLE PHARMACEUTICALS 2005-08-25 — — US disclosed
EP-1373288-B1 PROCESS FOR THE PREPARATION OF 2'-HALO-BETA-L-ARABINOFURANOSYL NUCLEOSIDES GILEAD SCIENCES INC (US) 2005-06-29 — — EP disclosed
EP-1519931-A2 CHIRAL 3,4-DIHYDRO-2H-PYRAN COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 2005-04-06 — — EP disclosed
US-6870048-B2 Process for the preparation of 2'-halo-β-L-arabinofuranosyl nucleosides TRIANGLE PHARMACEUTICALS (US) 2005-03-22 — — US disclosed
WO-2004002979-A2 CHIRAL 3,4-DIHYDRO-2H-PYRAN COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 2004-01-08 — — WO disclosed
US-20030060622-A1 Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides BUKWANG PHARMACEUTICAL IND CO., LTD. (KR) 2003-03-27 — — US disclosed
US-6468688-B2 CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE PINNACLE VRB LIMITED (AU) 2002-10-22 — — US disclosed
WO-2002079213-A1 PROCESS FOR THE PREPARATION OF 2'-HALO-$G(B)-L-ARABINOFURANOSYL NUCLEOSIDES TRIANGLE PHARMACEUTICALS, INC. (US) 2002-10-10 — — WO disclosed
EP-1240176-A1 BENZOPHENONE GLYCOPYRANOSIDES, PREPARATION AND THERAPEUTIC USE FOURNIER INDUSTRIE ET SANTE (FR) 2002-09-18 — — EP disclosed
US-20010028977-A1 Charging, discharging efficiency; vanadium electrolyte JD HOLDING INC. (KY) 2001-10-11 — — US disclosed
WO-2001047940-A1 BENZOPHENONE GLYCOPYRANOSIDES, PREPARATION AND THERAPEUTIC USE FOURNIER INDUSTRIE ET SANTE (FR) 2001-07-05 — — WO disclosed
US-6143443-A ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE PINNACLE ARB LIMITED (AU) 2000-11-07 — — US disclosed
EP-0729648-A4 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LTD (AU) 1997-01-02 — — EP disclosed
EP-0729648-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-09-04 — — EP disclosed
WO-1995012219-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1995-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050230660-A1 Chiral 3,4-dihydro-2h-pyran compounds HPD, DHPS, DDT PTPN1 938/4885POLB 2582/4885GAA 2431/4885
US-20050187384-A1 Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides FUCA2, FUCA1, GALE PTPN1 4803/4885POLB 511/4885GAA 351/4885
US-20030060622-A1 Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides FUCA2, FUCA1, GALE PTPN1 4817/4885POLB 455/4885GAA 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.